SRZN
BEARISH
$31.56
Live
Surrozen, Inc. · NASDAQ
Target $38.75
(+22.8%)
$5.9
52W Range
$33.22
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$371.23M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
SRZN exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is operating with negative equity (Price/Book: -1.64) and an unsustainable Price/Sales ratio of 106.77, suggesting the current valuation is entirely speculative. While the current ratio of 9.22 provides a temporary liquidity cushion, the combination of declining revenue (-19.4% YoY) and massive earnings misses (most recent surprise -678.8%) points to a failing operational model. The recent price surge is disconnected from all deterministic health and value metrics.
Key Strengths
Strong short-term liquidity (Current Ratio: 9.22)
Significant 1-year price momentum (+223.8%)
Analyst target price ($38.75) suggests potential upside based on pipeline
High quick ratio (9.01) indicating minimal reliance on inventory
Recent 6-month price appreciation (+132.4%)
Key Risks
Extreme valuation (P/S ratio of 106.77 is decoupled from revenue)
Negative shareholder equity (Price/Book: -1.64)
Severe operational inefficiency (Operating Margin: -2393.75%)
Consistent and massive earnings misses (Average surprise -298.89%)
Declining revenue growth (-19.4% YoY and Q/Q)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
13
Weak
5
20
30
10
0
AI Verdict
Speculative Bubble
Key drivers: Piotroski F-Score 1/9, Negative Equity, Extreme P/S Ratio, Revenue Contraction
Confidence
90%
Value
5/100
Stock trades at an extreme premium to sales with no earnings to support the valuation.
Positives
No standout positives identified.
Watchpoints
- P/S of 106.77
- Negative P/B
- No Graham Number available due to lack of earnings/assets
Future
20/100
Growth metrics are trending downward across all primary revenue and earnings indicators.
Positives
- Analyst target price is higher than current price
Watchpoints
- Negative YoY revenue growth
- Negative Q/Q revenue growth
- Severe EPS deterioration
Past
30/100
Historical performance shows a pattern of volatility and failure to meet financial targets.
Positives
- Strong 1-year price recovery
Watchpoints
- 5-year return is -78.7%
- Chronic failure to meet earnings estimates
Health
10/100
Despite high cash-like liquidity, the underlying financial health is critical.
Positives
- High Current Ratio (9.22)
Watchpoints
- Piotroski F-Score 1/9
- Negative Book Value
- Extreme Operating Losses
Dividend
0/100
Non-dividend paying growth/speculative stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$31.56
Analyst Target
$38.75
Upside/Downside
+22.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SRZN and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SRZN
Surrozen, Inc.
Primary
|
-78.7% | +192.2% | +223.8% | +132.4% | +22.9% | +11.9% |
|
PBYI
Puma Biotechnology, Inc.
Peer
|
-24.3% | +142.1% | +151.4% | +33.8% | +17.9% | -7.2% |
|
NAGE
Niagen Bioscience, Inc.
Peer
|
-45.0% | +228.0% | -23.6% | -37.2% | -2.3% | +4.9% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
SOPH
SOPHiA GENETICS SA
Peer
|
-68.5% | +3.5% | +86.6% | +22.5% | +7.5% | +12.3% |
SRZ
Surrozen, Inc.
Primary
5Y
-78.7%
3Y
+192.2%
1Y
+223.8%
6M
+132.4%
1M
+22.9%
1W
+11.9%
PBY
Puma Biotechnology, Inc.
Peer
5Y
-24.3%
3Y
+142.1%
1Y
+151.4%
6M
+33.8%
1M
+17.9%
1W
-7.2%
NAG
Niagen Bioscience, Inc.
Peer
5Y
-45.0%
3Y
+228.0%
1Y
-23.6%
6M
-37.2%
1M
-2.3%
1W
+4.9%
BNR
Burning Rock Biotech Limited
Peer
5Y
-89.9%
3Y
+6.9%
1Y
+414.2%
6M
+415.7%
1M
+65.3%
1W
+9.6%
SOP
SOPHiA GENETICS SA
Peer
5Y
-68.5%
3Y
+3.5%
1Y
+86.6%
6M
+22.5%
1M
+7.5%
1W
+12.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-8.85
PEG Ratio
N/A
P/B Ratio
-1.64
P/S Ratio
106.77
EV/Revenue
80.5
EV/EBITDA
-6.74
Market Cap
$371.23M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-2393.75%
Gross Margin
N/A
ROE
N/A
ROA
-35.75%
Growth
Revenue and earnings growth rates
Revenue Growth
-19.4%
Earnings Growth
N/A
Q/Q Revenue Growth
-19.39%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
9.22
Strong
Quick Ratio
9.01
Excellent
Cash/Share
$7.77
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-2393.8%
Net Margin
-34689.2%
Total Assets
$0.1B
Liabilities
$0.3B
Equity
$-0.2B
Debt/Equity
-1.53x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-23
$-9.62
-678.8% surprise
2025-11-07
$-3.6
-208.1% surprise
2025-08-08
$-1.14
+7.5% surprise
2025-05-09
$-7.43
-316.2% surprise
Healthcare Sector Comparison
Comparing SRZN against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Revenue Growth
-19.4%
This Stock
vs
142.9%
Sector Avg
-113.6%
(Slower)
Current Ratio
9.22
This Stock
vs
4.65
Sector Avg
+98.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SRZN
Surrozen, Inc.
|
BEARISH | $371.23M | - | -% | -% | $31.56 | |
|
PBYI
Puma Biotechnology, Inc.
|
BEARISH | $368.35M | 11.87 | 28.0% | 13.6% | $7.24 | Compare |
|
NAGE
Niagen Bioscience, Inc.
|
NEUTRAL | $375.58M | 23.45 | 28.3% | 13.4% | $4.69 | Compare |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | Compare |
|
SOPH
SOPHiA GENETICS SA
|
BEARISH | $378.41M | - | -110.0% | -102.2% | $5.28 | Compare |
SRZN
Surrozen, Inc.
BEARISH
Mkt Cap
$371M
P/E
-
ROE
-%
Price
$31.56
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | LI YANG | Officer | Gift | 1,666 | - |
| 2026-03-24 | TCG CROSSOVER GP II, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | 121,881 | $3,012,768 |
| 2026-03-16 | TCG CROSSOVER GP II, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | 48,997 | $1,220,362 |
| 2026-02-12 | TCG CROSSOVER GP II, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | 18,856 | $444,844 |
| 2026-02-03 | TCG CROSSOVER GP II, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | 9,357 | $202,534 |
| 2026-01-20 | COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | 32,507 | $641,597 |
| 2026-01-20 | KUTZKEY TIM PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 32,507 | $641,597 |
| 2026-01-14 | COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | 17,993 | $357,353 |
| 2026-01-14 | KUTZKEY TIM PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 17,993 | $357,353 |
| 2026-01-06 | COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | 15,100 | $300,297 |
| 2026-01-06 | KUTZKEY TIM PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 15,100 | $300,297 |
| 2026-01-05 | WILLIAMS CHARLES O | Chief Operating Officer | Sale | 1,566 | $31,109 |
| 2026-01-05 | LI YANG | Officer | Sale | 1,118 | $22,209 |
| 2026-01-02 | WILLIAMS CHARLES O | Chief Operating Officer | Stock Award | 3,500 | - |
| 2026-01-02 | LI YANG | Officer | Stock Award | 2,500 | - |
LI YANG
Officer
2026-03-31
1,666 shares
TCG CROSSOVER GP II, L.L.C
Beneficial Owner of more than 10% of a Class of Security
2026-03-24
121,881 shares
·
$3,012,768
TCG CROSSOVER GP II, L.L.C
Beneficial Owner of more than 10% of a Class of Security
2026-03-16
48,997 shares
·
$1,220,362
TCG CROSSOVER GP II, L.L.C
Beneficial Owner of more than 10% of a Class of Security
2026-02-12
18,856 shares
·
$444,844
TCG CROSSOVER GP II, L.L.C
Beneficial Owner of more than 10% of a Class of Security
2026-02-03
9,357 shares
·
$202,534
COLUMN GROUP III GP, L.P
Beneficial Owner of more than 10% of a Class of Security
2026-01-20
32,507 shares
·
$641,597
KUTZKEY TIM PH.D.
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-20
32,507 shares
·
$641,597
COLUMN GROUP III GP, L.P
Beneficial Owner of more than 10% of a Class of Security
2026-01-14
17,993 shares
·
$357,353
KUTZKEY TIM PH.D.
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-14
17,993 shares
·
$357,353
COLUMN GROUP III GP, L.P
Beneficial Owner of more than 10% of a Class of Security
2026-01-06
15,100 shares
·
$300,297
KUTZKEY TIM PH.D.
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-06
15,100 shares
·
$300,297
WILLIAMS CHARLES O
Chief Operating Officer
2026-01-05
1,566 shares
·
$31,109
LI YANG
Officer
2026-01-05
1,118 shares
·
$22,209
WILLIAMS CHARLES O
Chief Operating Officer
2026-01-02
3,500 shares
LI YANG
Officer
2026-01-02
2,500 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
4 analysts
Cantor Fitzgerald
2026-03-24
Overweight
Overweight
HC Wainwright & Co.
2026-03-24
Buy
Buy
Cantor Fitzgerald
2026-02-19
Overweight
Past News Coverage
Recent headlines mentioning SRZN from our newsroom.
Newest → oldest
No matching news yet.